Moaddel; Ruin

Patent Applications and Registrations

Patent applications and USPTO patent grants for Moaddel; Ruin.The latest application filed is for "crystal forms and methods of synthesis of (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine".

Company Profile

3.4.11

Moaddel; Ruin - Bel Air MD
Moaddel; Ruin - Germantown MD

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Crystal Forms And Methods Of Synthesis Of (2r, 6r)-hydroxynorketamine And (2s, 6s)-hydroxynorketamine App 20210139411 - Thomas; Craig ; et al.	2021-05-13
Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine Grant 10,919,842 - Thomas , et al. February 16, 2	2021-02-16
Use Of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine And Other Stereoisomeric Dehydro And Hydroxylated Metabolites Of (r,s)-ketamine In The Treatment Of Depression And Neuropathic Pain App 20200360393 - WAINER; IRVING W. ; et al.	2020-11-19
Crystal Forms And Methods Of Synthesis Of (2r, 6r)-hydroxynorketamine And (2s, 6s)-hydroxynorketamine App 20190135732 - Thomas; Craig ; et al.	2019-05-09
Methods Of Using (2r, 6r)-hydroxynorketamine And (2s, 6s)-hydroxynorketamine In The Treatment Of Depression, Anxiety, Anhedonia, Fatigue, Suicidal Ideation, And Post Traumatic Stress Disorders App 20190083420 - Wainer; Irving ; et al.	2019-03-21
Use Of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine And Other Stereoisomeric Dehydro And Hydroxylated Metabolites Of (r,s)- Ketamine In The Treatment Of Depression And Neuropathic Pain App 20180098993 - WAINER; IRVING W. ; et al.	2018-04-12
Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain Grant 9,867,830 - Wainer , et al. January 16, 2	2018-01-16
Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain Grant 9,650,352 - Wainer , et al. May 16, 2	2017-05-16
Use Of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine And Other Stereoisomeric Dehydro And Hydroxylated Metabolites Of (r,s)- Ketamine In The Treatment Of Depression And Neuropathic Pain App 20170049780 - WAINER; IRVING W. ; et al.	2017-02-23
The Use Of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine And Other Stereoisomeric Dehydro And Hydroxylated Metabolites Of (r,s)- Ketamine In The Treatment Of Depression And Neuropathic Pain App 20140296241 - Wainer; Irving W. ; et al.	2014-10-02
Computer-based model for identification and characterization of non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors Grant 7,749,984 - Wainer , et al. July 6, 2	2010-07-06
Computer-based model for identification and characterization of non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors App 20050033522 - Wainer, Irving W. ; et al.	2005-02-10
Multiple binding moiety chromatography device, methods of using and methods of making same App 20030166301 - Wainer, Irving W. ; et al.	2003-09-04
Novel parallel throughput system App 20030150812 - Wainer, Irving ; et al.	2003-08-14
Immobilized G-protein coupled receptors on liquid chromatography stationary phases and use thereof for on-line screening App 20030006192 - Wainer, Irving ; et al.	2003-01-09

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.